Characterization of CS1003, A Novel Clinical-Stage PD-1 Monoclonal Antibody

Platinum-based chemotherapy (chemo) with CS1001, an anti-PD-L1 antibody, for first-line advanced NSCLC: preliminary results from Phase Ib cohorts of CS1001-101 study

#3260 Preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation

CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy

A Phase Ib Trial of the Anti - PD - L1 Human Monoclonal Antibody, CS1001, in Patients with Advanced Solid Tumors or Lymphomas: Preliminary Efficacy and Safety Results from 4 Cohorts

A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas

GEMSTONE-302: a Phase III Study of Platinum-Based Chemotherapy with or without CS1001, an Anti-PD-L1 Antibody in Chemo-Naïve Advanced Non–Small Cell Lung Carcinoma (NSCLC)

Gemstone-301: A Phase III Clinical Trial of CS1001 As Consolidation Therapy in Subjects with Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed after Prior Concurrent/Sequential Chemoradiotherapy (CRT)